HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer

被引：0
|
作者：
Moreno Olmedo, E. [1 ]
Nagore, G. [2 ]
Suarez Gironzini, V.
Minguez, C. [3 ]
Gomez, E. [4 ]
Garcia, A. [4 ]
Ciapa, V. [5 ]
Marrone, I. [1 ]
Lopez, E. [1 ]
机构：
[1] Hosp Vithas La Milagrosa, Radiat Oncol, GenesisCare Spain, Madrid, Spain
[2] Hosp Vithas Alicante, GenesisCare Spain, Radiat Oncol, Alicante, Spain
[3] Hosp Vithas La Milagrosa, GenesisCare Spain, Radiphys, Madrid, Spain
[4] Hosp Vithas Alicante, Radiophys, GenesisCare Spain, Alicante, Spain
[5] Hosp Vithas La Milagrosa, Genesiscare Spain, Radiat Oncol Nurse, Madrid, Spain
来源：
RADIOTHERAPY AND ONCOLOGY | 2021年 / 161卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1369
引用
收藏
页码：S1122 / S1123
页数：2
相关论文
共 50 条
  • [1] HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
    Moreno Olmedo, E.
    Nagore, G.
    Suarez-Gironzini, V.
    Minguez, C.
    Gomez, E.
    Garcia, A.
    Ciapa, V.
    Marrone, I.
    Lopez, E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S123 - S123
  • [2] HDR brachytherapy as monotherapy for low and intermediate risk prostate cancer
    Gaudet, M.
    Pharand-Charbonneau, M.
    Wright, D.
    Desrosiers, M.
    Haddad, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S1188 - S1188
  • [3] HDR brachytherapy in monotherapy of one fraction in patients with prostate cancer at low risk
    Orduz Arenas, A. C.
    Jimenez Garcia, I.
    Martinez Gutierrez, R.
    Cucarella Beltran, P.
    Blanco Parajon, S.
    Gonzalez Suarez, H. A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S947 - S947
  • [4] Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients
    Funk, R. K.
    Davis, B. J.
    Mynderse, L. A.
    Wilson, T. M.
    Deufel, C. L.
    Furutani, K. M.
    Pisansky, T. M.
    Haddock, M. G.
    Choo, C. R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E213 - E214
  • [5] Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients
    Routman, David M.
    Funk, Ryan K.
    Stish, Bradley J.
    Mynderse, Lance A.
    Wilson, Torrence M.
    McLaren, Robert
    Harmsen, W. Scott
    Mara, Kristin
    Deufel, Christopher L.
    Furutani, Keith M.
    Haddock, Michael G.
    Pisansky, Thomas M.
    Choo, C. Richard
    Davis, Brian J.
    [J]. BRACHYTHERAPY, 2019, 18 (01) : 1 - 7
  • [6] Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer
    Muralidhar, Vinayak
    Mahal, Brandon A.
    Ziehr, David R.
    Chen, Yu-Wei
    Nezolosky, Michelle D.
    Viswanathan, Vidya B.
    Beard, Clair J.
    Devlin, Phillip M.
    Martin, Neil E.
    Orio, Peter F., III
    Nguyen, Paul L.
    [J]. BRACHYTHERAPY, 2015, 14 (04) : 511 - 516
  • [7] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] HDR MONO-BRACHYTHERAPY FOR LOW AND INTERMEDIATE RISK CANCER OF THE PROSTATE
    Johansson, B.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S214 - S214
  • [9] LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
    Boehle, Andreas
    Zywietz, Dorothea
    Robrahn-Nitschke, Irina
    Lusch, Achim
    Koenig, Inke R.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 454.e17 - 454.e24
  • [10] Survival of Low-Risk and Intermediate-Risk Prostate Cancer Patients Treated with IMRT Or Brachytherapy
    Podder, T.
    Dey, A.
    Datta, S.
    Biswas, T.
    [J]. MEDICAL PHYSICS, 2020, 47 (06) : E318 - E318
12345